Patents by Inventor Raymond Andersen

Raymond Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12011421
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: June 18, 2024
    Assignee: CAVA HEALTHCARE INC.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Publication number: 20230167115
    Abstract: The present disclosure relates to the use of antiviral agents that are cladoniamides and derivatives thereof such as the compound Formula I, for example, for the treatment of viral infections such as those caused by coronaviruses and/or flaviviruses. The present disclosure also includes antiviral agents and methods for their preparation.
    Type: Application
    Filed: April 23, 2021
    Publication date: June 1, 2023
    Inventors: François Jean, Raymond Andersen, David Williams, Julian Davies, Rory Long, Tirosh Shapira, Weeda Morsal Mamozai
  • Publication number: 20220062195
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 3, 2022
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 11197832
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: December 14, 2021
    Assignee: Cava Healthcare Inc.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Publication number: 20200375917
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 3, 2020
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 10751296
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 25, 2020
    Assignee: CAVA HEALTHCARE INC.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Publication number: 20170319508
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: January 25, 2017
    Publication date: November 9, 2017
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Publication number: 20170298033
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 19, 2017
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, British Columbia Cancer Agency Branch
    Inventors: Raymond ANDERSEN, Marianne Dorothy SADAR, Kunzhong JIAN, Nasrin R. MAWJI, Jun WANG, Carmen Adriana BANUELOS, Yu-Chi YANG
  • Patent number: 9000050
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: April 7, 2015
    Assignee: The University of British Columbia
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Patent number: 8956824
    Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: February 17, 2015
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Alice Mui, Christopher Ong, Gerald Krystal, Raymond Andersen
  • Patent number: 8765994
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: July 1, 2014
    Assignee: The University of British Columbia
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Publication number: 20130217674
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Application
    Filed: August 22, 2011
    Publication date: August 22, 2013
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Patent number: 8431541
    Abstract: Particular naturally occurring glycosylated acyl-flavonols are now shown to be effective mammalian ?-amylase inhibitors. Such compounds can be obtained from plants of the genus Crocosmia and the compounds are useful in controlling starch digestion such as for management of glycemia in pre-diabetic or diabetic subjects, for management of obesity or for inhibiting oral caries or plaque formation.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: April 30, 2013
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Andrew C. Tarling, Raymond Andersen, Gary D. Brayer, Katherine Woods
  • Publication number: 20120129925
    Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.
    Type: Application
    Filed: August 19, 2011
    Publication date: May 24, 2012
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal, Lu Yang
  • Publication number: 20110263539
    Abstract: The present invention provides the use of pelorol analogs of Formula, (I) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.
    Type: Application
    Filed: June 21, 2007
    Publication date: October 27, 2011
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Raymond Andersen, Matthew Nodwell, Alice Mui
  • Publication number: 20110189107
    Abstract: Particular naturally occurring glycosylated acyl-flavonols, e.g.
    Type: Application
    Filed: October 16, 2008
    Publication date: August 4, 2011
    Applicant: The University of British Columbia
    Inventors: Stephen Withers, Andrew C. Tarling, Raymond Andersen, Gary D. Brayer, Katherine Woods
  • Publication number: 20100323990
    Abstract: The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.
    Type: Application
    Filed: June 21, 2007
    Publication date: December 23, 2010
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Raymond Andersen, Matthew Nodwell, Alice Mui
  • Publication number: 20100311094
    Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.
    Type: Application
    Filed: June 4, 2009
    Publication date: December 9, 2010
    Inventors: Alice Mui, Christopher Ong, Gerald Krystal, Raymond Andersen
  • Publication number: 20100280004
    Abstract: This invention provides compounds of Formula I. The compounds are correctors of ?F508 CFTR trafficking. Also provided are uses of compounds of Formula I for treatment, as well as methods of treatment, of cystic fibrosis.
    Type: Application
    Filed: July 3, 2008
    Publication date: November 4, 2010
    Inventors: Raymond Andersen, Robert Keyzers, Christopher Anthony Gray, David Y. Thomas, John W. Hanrahan, Graeme W. Carlile
  • Patent number: 7772397
    Abstract: This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: August 10, 2010
    Assignee: University of British Columbia
    Inventors: Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michel Roberge, Theresa Allen